Nykredit A/S’s Krystal Biotech KRYS Stock Holding History

Nykredit A/S’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$438K	Buy	+1,178	New	+$352K	﹤0.01%	729

Other funds holding KRYS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Nykredit A/S's KRYS Position: Q2 2026 in Review

Nykredit A/S opened a new position in Krystal Biotech (KRYS) in Q2 2026: 1,178 shares worth $438K. The stake represents ﹤0.01% of the portfolio and ranks #729 among its holdings.

330 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Nykredit A/S held 1,178 shares of Krystal Biotech worth $438K as of Q2 2026.
Krystal Biotech was a new Nykredit A/S position in Q2 2026.
Krystal Biotech made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #729 holding.
330 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.